Allogene Therapeutics. has been granted a patent for constitutively active chimeric cytokine receptors (CACCRs) that enhance the activation, proliferation, and potency of CAR-bearing immune cells. The patent details the structure and composition of these receptors, including specific amino acid sequences and substitutions. GlobalData’s report on Allogene Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Allogene Therapeutics, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Allogene Therapeutics's grant share as of July 2024 was 7%. Grant share is based on the ratio of number of grants to total number of patents.
Constitutively active chimeric cytokine receptors for immune cell enhancement
The patent US12043655B2 describes a novel constitutively active chimeric cytokine receptor (CACCR) designed to enhance immune responses, particularly in the context of cancer treatment. The CACCR is composed of two monomers, each featuring a transmembrane domain, a Janus Kinase (JAK)-binding domain, and a recruiting domain. The design includes specific amino acid sequences and substitutions, notably amino acids 478-582 from SEQ ID NO: 6, with substitutions such as S505N and W515K. The claims further detail variations of the JAK-binding domain, which can include JAK1, JAK2, JAK3, or TYK2, and specify the recruiting domain's potential sources, including various cytokine receptors like IL2Rb and IL7Ra.
Additionally, the patent outlines methods for creating engineered immune cells that incorporate the CACCR, including the use of expression vectors, such as lentiviral vectors, to introduce the necessary polynucleotides into immune cells, particularly T-cells. The engineered immune cells can express both a chimeric antigen receptor (CAR) and the CACCR, potentially in equal stoichiometric amounts. The patent also encompasses pharmaceutical compositions and kits containing these engineered immune cells, as well as methods for treating cancers, including both solid and liquid tumors, by administering these cells to patients. This innovative approach aims to leverage the enhanced signaling capabilities of the CACCR to improve therapeutic outcomes in cancer immunotherapy.
To know more about GlobalData’s detailed insights on Allogene Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
